1-11 of 11
David Hong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial: SABR and Ipilimumab—Response

Free
Chad Tang, James W. Welsh, David Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1): 321.
https://doi.org/10.1158/1078-0432.CCR-16-2621
Published: 02 January 2017
View articletitled, Phase I Trial: SABR and Ipilimumab—Response
Open the PDF for Phase I Trial: SABR and Ipilimumab—Response in another window
Journal Articles

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Free
Pamela Munster, Rahul Aggarwal, David Hong, Jan H.M. Schellens, Ruud van der Noll, Jennifer Specht, Petronella O. Witteveen, Theresa L. Werner, E. Claire Dees, Emily Bergsland, Neeraj Agarwal, Joseph F. Kleha, Michael Durante, Laurel Adams, Deborah A. Smith, Thomas A. Lampkin, Shannon R. Morris, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 1932–1939.
https://doi.org/10.1158/1078-0432.CCR-15-1665
Published: 14 April 2016
View articletitled, First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Open the PDF for First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies in another window
Includes: Supplementary data
Journal Articles

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Free
Ana M. Gonzalez-Angulo, Funda Meric-Bernstam, Sant Chawla, Gerald Falchook, David Hong, Argun Akcakanat, Huiqin Chen, Aung Naing, Siqing Fu, Jennifer Wheler, Stacy Moulder, Thorunn Helgason, Shaoyi Li, Ileana Elias, Neil Desai, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5474–5484.
https://doi.org/10.1158/1078-0432.CCR-12-3110
Published: 01 October 2013
View articletitled, Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
Open the PDF for Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors

Free
David Hong, Rabih Said, Gerald Falchook, Aung Naing, Stacy Moulder, Apostolia-Maria Tsimberidou, Gerald Galluppi, Naveen Dakappagari, Chris Storgard, Razelle Kurzrock, Lee S. Rosen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4824–4831.
https://doi.org/10.1158/1078-0432.CCR-13-0477
Published: 02 September 2013
View articletitled, Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
Open the PDF for Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

Free
John Moroney, Siqing Fu, Stacy Moulder, Gerald Falchook, Thorunn Helgason, Charles Levenback, David Hong, Aung Naing, Jennifer Wheler, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (20): 5796–5805.
https://doi.org/10.1158/1078-0432.CCR-12-1158
Published: 14 October 2012
View articletitled, Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity
Open the PDF for Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity in another window
Journal Articles

Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience

Free
Jennifer Wheler, Apostolia M. Tsimberidou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2922–2929.
https://doi.org/10.1158/1078-0432.CCR-11-2217
Published: 14 May 2012
View articletitled, Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
Open the PDF for Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer

Free
Aung Naing, Razelle Kurzrock, Angelika Burger, Sachin Gupta, Xiudong Lei, Naifa Busaidy, David Hong, Helen X. Chen, Lawrence A. Doyle, Lance K. Heilbrun, Eric Rohren, Chaan Ng, Chandtip Chandhasin, Patricia LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 6052–6060.
https://doi.org/10.1158/1078-0432.CCR-10-2979
Published: 14 September 2011
View articletitled, Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
Open the PDF for Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer in another window
Journal Articles

Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience

Free
Apostolia Maria Tsimberidou, Katherine Letourneau, Sijin Wen, Jennifer Wheler, David Hong, Aung Naing, Nancy G. Iskander, Cynthia Uehara, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4110–4118.
https://doi.org/10.1158/1078-0432.CCR-10-3095
Published: 15 June 2011
View articletitled, Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience
Open the PDF for Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience in another window
Includes: Supplementary data
Journal Articles

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

Free
Rajul K. Jain, J. Jack Lee, David Hong, Maurie Markman, Jing Gong, Aung Naing, Jennifer Wheler, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1289–1297.
https://doi.org/10.1158/1078-0432.CCR-09-2684
Published: 15 February 2010
View articletitled, Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
Open the PDF for Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse in another window
Includes: Supplementary data
Journal Articles

Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas

Free
David J. Stewart, Jean-Pierre Issa, Razelle Kurzrock, Maria I. Nunez, Jaroslav Jelinek, David Hong, Yasuhiro Oki, Zhong Guo, Sanjay Gupta, Ignacio I. Wistuba
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3881–3888.
https://doi.org/10.1158/1078-0432.CCR-08-2196
Published: 01 June 2009
View articletitled, Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
Open the PDF for Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas in another window
Journal Articles

Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers

Free
Fadi Braiteh, Andres O. Soriano, Guillermo Garcia-Manero, David Hong, Marcella M. Johnson, Leandro De Padua Silva, Hui Yang, Stefanie Alexander, Johannes Wolff, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6296–6301.
https://doi.org/10.1158/1078-0432.CCR-08-1247
Published: 30 September 2008
View articletitled, Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
Open the PDF for Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers in another window